Does adjuvant chemotherapy improve survival for women with early-stage uterine leiomyosarcoma?

Impact of Surgery on the Evolution of Uterine Sarcomas

“…Reoperation for completion surgery and staging is important because 15% of patients will be upstaged by re-exploration In our data for the non-morcellated group, a 34.4% recurrence rate was observed comparable to the literature (20%-42.8%) (2,4). When a morcellation was done, the rate of recurrence was 64.3% (1).…”

Clinical outcome affected by tumor morcellation in unexpected early uterine leiomyosarcoma

“…The main site of first recurrence in LMS patients was found to be the extra-pelvic region, whereas the lungs were reported to be the most common site of recurrence [27,28]. All of our patients with distant recurrence showed lung metastasis.…”

“…All of our patients with distant recurrence showed lung metastasis. The recurrence rate in the pelvic cavity is reported in the range of 6e19% at median follow-up periods of 16e42 months for traditional open surgery [28,29]. The rate of pelvic recurrence increased with time and could be as high as 75% among the survivors at 10 years after surgery [30].…”

Current Status of Uterine Leiomyosarcoma in the Tohoku Region: Results of the Tohoku Translational Center Development Network Survey

“…Therefore, many ULMS patients have been treated at general hospitals, unlike those with cervical cancer, endometrial cancer, or ovarian cancer. Furthermore, although patients with ULMS had good PS and a high rate of complete or optimal surgery, the long-term prognosis remains poor [8][9][10][11][12][13]. Although previous studies [4,8,13,14] have revealed that adjuvant therapy was not associated with a significant survival benefit even in early stage ULMS, the effects of a new combination chemotherapy or molecular-targeted therapy have been evaluated in clinical trials to improve the prognosis of patients with ULMS.…”

“…Furthermore, although patients with ULMS had good PS and a high rate of complete or optimal surgery, the long-term prognosis remains poor [8][9][10][11][12][13]. Although previous studies [4,8,13,14] have revealed that adjuvant therapy was not associated with a significant survival benefit even in early stage ULMS, the effects of a new combination chemotherapy or molecular-targeted therapy have been evaluated in clinical trials to improve the prognosis of patients with ULMS. Combination therapy of gemcitabine and docetaxel has been a standard regimen of chemotherapy according to results of phase II trials [15][16][17], and there have been favorable results from a phase II trial (SARC 005) regarding adjuvant treatment with docetaxel and gemcitabine followed by doxorubicin in patients with uterus-limited ULMS [18].…”